文献速递肿瘤 PET/CT

肉瘤患者中[18F]FDG PET/CT与[68Ga]Ga-HX01 PET/MR的头对头评估

Head-to-head evaluation of [18F]FDG PET/CT and [68Ga]Ga-HX01 PET/MR in sarcoma patients.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-02-20

本研究回顾性纳入21例肉瘤患者,在1周内分别行[68Ga]Ga-HX01 PET/MR与[18F]FDG PET/CT头对头比较。患者水平分析显示两种示踪剂病灶检出诊断效能相当(P=1.0);[68Ga]Ga-HX01的SUVmax在患者水平和病灶水平均显著低于[18F]FDG;[68Ga]Ga-HX01在接受造血细胞因子的患者中更受青睐。

要点

  • 患者水平分析显示[68Ga]Ga-HX01 PET/MR与[18F]FDG PET/CT病灶检出诊断效能相当(P=1.0)。
  • [68Ga]Ga-HX01的SUVmax在患者水平(4.64±1.90 vs 9.43±6.17,P=0.002)低于[18F]FDG。
  • 病灶水平[68Ga]Ga-HX01检出94个病灶 vs [18F]FDG 92个,差异未达统计学显著(P=0.678)。

核心结论

  • [68Ga]Ga-HX01 PET在肉瘤中提供与[18F]FDG PET/CT相当的诊断效能,在特定临床场景中具有潜在优势;需要更大样本量验证这些发现。

研究设计与样本

  • 回顾性分析2022年6月29日至2023年12月21日期间接受[68Ga]Ga-HX01 PET/MR和[18F]FDG PET/CT的肉瘤患者影像数据,两种检查在一周内分开两天进行。
  • 纳入21例患者,平均年龄45.81±19.99岁;其中4例为初诊分期,其余17例为检测复发。
  • 收集所有病灶的位置、数量和PET特征,评估两种示踪剂之间的关系。
  • 临床试验注册号NCT05490849和NCT06416774。

主要发现

  • 患者水平分析中,[68Ga]Ga-HX01 PET/MR病灶检出诊断效能与[18F]FDG PET/CT相当(P=1.0)。
  • 全部患者中[68Ga]Ga-HX01的SUVmax(4.64±1.90)显著低于[18F]FDG(9.43±6.17,P=0.002)。
  • 病灶水平分析中,[68Ga]Ga-HX01较[18F]FDG多检出2个病灶,但差异未达统计学显著(94 vs 92,P=0.678)。
  • 全部病灶的SUVmax在[68Ga]Ga-HX01为3.47±1.68,低于[18F]FDG的5.82±4.81(P=0.003)。
  • [68Ga]Ga-HX01在接受造血细胞因子的患者中更受青睐。

临床怎么用

  • 作者结论认为[68Ga]Ga-HX01 PET在肉瘤中诊断效能与[18F]FDG PET/CT相当,在特定临床场景中具有潜在优势,并指出需要更大样本量验证。

局限性

  • 原文结论指出需要更大样本量验证这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Tumor-associated neovasculature and energy metabolism reprogramming serve as critical indicators of tumor proliferation, progression, invasion, and metastasis. This study conducted a head-to-head clinical investigation and comparison of [18F]FDG and [68Ga]Ga-HX01 PET by reflecting neovasculature and glucose metabolism in sarcoma patients, respectively. METHODS: We reviewed the imaging data of sarcoma patients who underwent [68Ga]Ga-HX01 PET/MR and [18F]FDG PET/CT from June 29, 2022, to December 21, 2023. The two imaging modalities were performed on two separate days within one week of each other. A cohort of 21 patients with an average age of 45.81 ± 19.99 years were enrolled. The location, number and PET characteristics of all lesions were collected. The relationships between the two tracers were evaluated. RESULTS: Among the 21 patients, 4 underwent imaging for initial disease staging, while the remaining 17 were imaged to detect recurrences. Patient-based analysis revealed that [68Ga]Ga-HX01 PET/MR diagnostic performance was equivalent to [18F]FDG PET/CT in lesion detection (P = 1.0). The SUVmax value of [68Ga]Ga-HX01 (4.64 ± 1.90) was significantly lower than that of [18F]FDG (9.43 ± 6.17, P = 0.002) across all patients. In terms of lesion-based analysis, [68Ga]Ga-HX01 identified two additional lesions compared to [18F]FDG, though this difference was not statistically significant (94 vs. 92, P = 0.678). The SUVmax value for all lesions with [68Ga]Ga-HX01 (3.47 ± 1.68) was also lower than that with [18F]FDG (5.82 ± 4.81, P = 0.003). Notably, [68Ga]Ga-HX01 was preferred in patients receiving hematopoietic cytokines. CONCLUSION: [68Ga]Ga-HX01 PET offers comparable diagnostic efficacy to [18F]FDG PET/CT in sarcoma, with potential advantages in specific clinical scenarios. Larger cohorts are needed to validate these findings. CLINICAL TRIAL REGISTRATION: NCT05490849 and NCT06416774.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Zhang X, Gai Y, Ye T, et al. Head-to-head evaluation of [18F]FDG PET/CT and [68Ga]Ga-HX01 PET/MR in sarcoma patients. Eur J Nucl Med Mol Imaging. 2025. PMID: 39976700. doi:10.1007/s00259-025-07130-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。